Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Search Icon
Search Icon
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

AbortionFetal Tissue, Stem Cells & Bioethics

Dr. David Prentice: U.S. Gov’t Must Stop Using Aborted Baby Parts for Research

Charlotte Lozier Institute’s Vice President and Research Director, Dr. David Prentice, joined the hosts of EWTN’s Morning Glory to discuss a letter from four dozen pro-life groups to U.S. Department of Health and Human Services Secretary Alex Azar calling for an end to government-sponsored research using tissue from aborted babies. Dr. Prentice explains the ethical alternatives and the need to lead the way in cutting-edge science.

 

Click to listen to the interview.

 

 

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

Abortion Reporting: Kentucky (2025)

October 5, 2026
Please login to bookmark Close

Abortion Reporting: Alabama (2025)

October 5, 2026
Please login to bookmark Close

Abortion Reporting: Virginia (2024)

October 5, 2026
Please login to bookmark Close

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image